Digital Therapeutics - Market Report

Market Overview

The digital therapeutics market is one of the fastest-growing areas of healthtech, with the global market size expected to reach $42 billion by 2032 with a CAGR of 23.2%. North America currently dominates this market with a share of 47%. This growth is propelled by the rising prevalence of chronic diseases, growing digitalization and increasing demand for patient-centered, cost-effective care.

Market Segmentation

By Platform

1. Software and Services: Apps (mobile, AR/VR, wearables), telehealth platforms, behavioral modification programs

2. Devices: Physical hardware that has integrated software and is used for therapeutic purposes (e.g. wearable sensors, continuous glucose monitor, smart inhalers)

By Therapeutic Focus

In terms of application, the market is segmented by prevention and treatment. Within that it is further sub-segmented into specific therapeutic focus areas: 

1. Behavioral and Mental Health: Digital solutions to manage anxiety, depression, substance use disorders, ADHD and other conditions, includes telehealth platforms, virtual cognitive behavioral therapy, and AI-powered chatbots

2. Cardiometabolic Conditions: Solutions for conditions like diabetes, obesity, and cardiovascular disease, including wearable devices, personalized lifestyle programs, and medication adherence apps

3. Physical Conditions: Solutions for physical conditions like musculoskeletal conditions, women's health, cancer, respiratory disease and gastrointestinal disorders are emerging.

By Sales Channel

1. B2B2C: Selling DTx to healthcare providers, payers (insurance companies), employers, and pharmaceutical companies who distribute to patients/ consumers supports the widespread adoption of digital therapeutics in clinical and corporate wellness programs

   1. Prescription: Physicians prescribe the DTx and insurance covers it.

   2. Employer/ Payer Coverage: Employers/ Payers may purchase DTx solutions for employees/ members, often to address chronic diseases or reduce healthcare costs. The employer/payer typically pays a set fee per month per employee/member. 

2. B2C: Selling DTx directly to patients or consumers over-the-counter or direct-to-consumer

Customer Demographics

There are three key customers within the digital therapeutics market:

1. Patients (end-users) who use DTx to manage or prevent chronic conditions, improve health outcomes and get better access to health care

2. Healthcare Providers who prescribe and monitor patients’ use of DTx as part of an overall treatment plan

3. Healthcare Payers who determine which DTx will be reimbursed and covered by insurance plans

End-consumers can be segmented by: 

1. Insurance Coverage

   1. Patients on Employer-Sponsored Plans (Largest Segment)

   2. Patients with Medicare/ Medicaid 

   3. Uninsured Patients: Limited adoption through direct-to-consumer (DTC) channels

2. Health Status

   1. Patients with Chronic Diseases: Largest user segment, likely individuals living with and managing diabetes, heart disease, obesity or mental health conditions

   2. At-Risk Individuals: Growing user segment, likely individuals who have identified risk factors (e.g. high BMI, hypertension), pre-diabetes or a family history of chronic conditions 

Growth Drivers & Trends

1. Expansion in Therapeutic Focus Areas: While digital therapeutics have traditionally been rooted in treatment for behavioral and mental health conditions and cardiometabolic conditions, the market is expanding to cover a wider range of therapeutic areas, including oncology, women’s health and pediatrics. This is leading to a fragmented market with many niche players addressing specialized health issues.

2. GLP-1s: The rise of GLP-1s is driving new investment opportunities for DTx solutions that are focused on companion lifestyle programs to support long-term weight management. Specifically, players like Omada, Teladoc and Lark Health are offering GLP-1 companion programs focused on medication adherence and behavior change tools. This is attractive to payers who are looking to reduce costs, given the high price tag of these medications. 

3. AI Integration: DTx solutions are leveraging AI to enable personalized, adaptive interventions that can enhance engagement and treatment efficacy. 

4. Regulation and Reimbursement: Supportive regulatory frameworks like The Access to Prescription for Digital Therapeutics Act, are encouraging the development and FDA-clearance of digital therapeutics. 

5. Mergers & Acquisitions: DTx mergers and acquisitions are becoming more common as the market matures and there are efforts to consolidate the many fragmented solutions and strategically align different areas of expertise. 

Challenges & Barriers

1. Regulatory Landscape: Digital therapeutics are subject to regulatory oversight and an evolving regulatory landscape. Although not all DTx solutions require prescription FDA-approval, they will still need to undergo FDA “authorization” or “clearance” which requires safety and efficacy testing. Navigating the rigorous regulatory and clinical requirements needed to demonstrate efficacy and safety is often complex, time-consuming and expensive.

   1. Leading Player Solutions: Companies like Pear Therapeutics (before acquisition) pioneered the "regulatory-first" approach, investing heavily in clinical trials before product development. Current leaders like Akili Interactive and AppliedVR are forming regulatory advisory boards with former FDA officials and partnering with academic medical centers to streamline clinical validation processes.

2. Business Model Sustainability: Demonstrating clear patient outcomes and economic value to payers and health systems is a challenge, especially as many DTx solutions struggle to maintain high user engagement and retention over time. Payers finding enough value for their members' health outcomes to provide coverage or reimbursements for DTx is essential to the survival of this market. 

   1. Leading Player Solutions: Omada Health has pioneered outcome-based contracting, where they only receive full payment if patients achieve specific health metrics (like HbA1c reduction). Virta Health offers a money-back guarantee to employers if employees don't achieve diabetes remission targets. These models align DTx company incentives with payer cost-reduction goals.

3. Healthcare System Integration: Integrating with existing healthcare systems so that the DTx can tie into a patient’s overall treatment plan has unique challenges. Specifically, there are issues with achieving interoperability across diverse health systems, ensuring seamless data flow between DTx and electronic health records (EHR), and ensuring the privacy and security of medical records and sensitive patient information. Physicians also often remain skeptical of DTx efficacy and outcomes and are hesitant to prescribe them as part of an overall treatment plan. 

   1. Leading Player Solutions: Teladoc has invested heavily in EHR integrations with Epic, Cerner, and other major systems, enabling seamless data flow. Companies like Dario Health have developed physician dashboards that provide real-time patient data and automated alerts, making it easier for providers to incorporate DTx into care workflows. Some leaders are also embedding clinical liaisons within health systems to drive provider adoption and address skepticism through education and support.

Competitive Landscape

Centralized Platforms: Key players in the market offering more comprehensive DTx solutions that cover a range of therapeutic areas are Omada Health, Teladoc Health, Lark Health 

Vertical Specialization: Key players in the market focused on a niche or specific vertical are Virta, Hinge, Click Therapeutics 

Investment Opportunities

1. New Therapeutic Areas: While digital therapeutics have gained traction in behavioral health and cardiometabolic conditions, significant white space opportunities remain in underserved therapeutic areas. Examples include, pediatric digital therapeutics (pediatric ADHD, autism spectrum disorders), which represents less than 5% of current DTx solutions despite children comprising 22% of the US population;  neurological conditions like Parkinson's, multiple sclerosis, and post-stroke rehabilitation which remain largely underserved; and women’s health conditions beyond fertility, with conditions like endometriosis, PCOS, and menopause management.

2. AI Enhancements: The rapidly evolving AI landscape coupled with improvements in sensor technology is unlocking new opportunities for DTx companies to personalize and adapt treatments. This is opening the door to transformative health solutions that not only treat and manage diseases but can also identify health risks and prevent health conditions.

3. Pharmaceutical Partnerships: As DTx companies increasingly form partnerships with pharmaceutical companies or develop companion programs for medications to improve long term patient outcomes and adherence there is an opportunity to further invest in these companies. These partnerships will likely drive adoption of DTx solutions and make a combined digital solution + medication a more mainstream approach to treatment. 

SWOT Analysis

Strengths 

• Cost Efficiency & Scalability: DTx solutions significantly reduce healthcare costs through decreased hospitalization rates and fewer in-person clinical visits, ultimately creating exceptional economies of scale compared to traditional therapeutic interventions.

• Increased Accessibility and Democratization of Healthcare: DTx platforms eliminate geographic barriers to specialized care, providing 24/7 access to evidence-based interventions, especially in underserved or remote areas. 

• Evidence-Based: Unlike wellness apps, DTX solutions go through rigorous regulatory and clinical validation to ensure that they are effective. This evidence-based approach aligns with the industry shift toward value-based care models, where payers tie payment to patient outcomes. 

Weaknesses 

• Sustained User Engagement and Adherence: One fundamental challenge for many DTx apps is user abandonment and drop off rates. Many apps struggle to even maintain a 10% retention rate after a year. 

• Business Model Uncertainty: Payers have been reluctant to cover this novel category of therapeutics. Payers often base their decisions on reimbursement and coverage on the availability of robust clinical evidence and given how relatively new this category is and struggles with user engagement and retention, there is limited data on the long term outcomes of this category.

• Regulatory Challenges: FDA clearance processes for DTx solutions average 18 months and cost $1.5-3M, creating significant barriers to market entry. Clearing regulatory and clinical requirements also often requires specialized expertise across multiple disciplines, increasing development complexity and overhead costs.

Opportunities 

• Personalized Medicine: Innovations in AI and machine learning can enhance the effectiveness and personalization of DTx solutions, unlocking new types of treatment and patient outcomes. This also aligns with the increased focus on personalization for the growing population of health conscious consumers 

• Scale Traditional Care Models: DTx solutions offer significant potential to extend the reach of traditional healthcare delivery systems by providing continuous monitoring and interventions outside clinical settings. Particularly for chronic condition management DTx solutions support a shift from episodic to continuous care models that can enable  earlier detection of condition deterioration and ultimately reduce acute care utilization This scalability allows providers to manage larger patient populations more efficiently, while maintaining or improving quality of care.

• Reimbursement Pathways: There is an opportunity for digital therapeutic companies to better communicate the value of their solutions to healthcare payers. This will require DTx companies to understand the priorities of payers and align their messaging and pricing models to match those priorities. Payers typically are looking for proof that a therapy reduces healthcare costs, often by lowering acute-care utilization. If DTx companies can successfully communicate this to payers they have an opportunity to facilitate broader adoption and access for patient populations.

Threats

• Market Competition: The DTx market is becoming increasingly competitive and saturated, with numerous startups and established companies vying for market share. 

• Big Tech Disruption: Major tech companies (Apple, Google, Amazon, Meta) are making strategic healthcare moves with unmatched resources and established consumer relationships. Their entry could disrupt the DTx market through bundled offerings or free features integrated into existing platforms.

• Regulatory Uncertainty: The regulatory landscape for digital therapeutics remains in flux as agencies worldwide develop frameworks to evaluate these novel technologies. Changes in regulatory requirements can significantly impact development timelines, go-to-market strategies, and investment returns. Inconsistency in approaches across different countries also adds complexity for global market expansion. There's also uncertainty around which DTx solutions will require full FDA approval versus clearance or authorization, creating potential competitive disadvantages for companies taking more rigorous regulatory pathways.

Conclusion

Digital therapeutics represents a rapidly expanding market poised to transform healthcare delivery through evidence-based digital interventions. The overall trajectory suggests digital therapeutics will become an increasingly integral component of standard care pathways 

 Despite challenges in the regulatory landscape and business model sustainability, the convergence of AI advancements, pharmaceutical partnerships, and expanding reimbursement pathways creates a favorable environment for innovation. For investors, opportunities exist in both platform plays and emerging therapeutic categories, particularly those leveraging AI for personalization and companies developing companion applications for pharmaceutical products.

The most successful DTx companies will be those that demonstrate measurable clinical outcomes, secure reimbursement pathways, and maintain high user engagement. As the industry matures, we anticipate increased consolidation through M&A activity, with platform companies expanding their therapeutic reach while specialized players deliver deeper solutions for specific conditions.

References

1. https://www.sciencedirect.com/science/article/abs/pii/S1359644624002356

2. https://www.mahalo.health/insights/challenges-for-digital-therapeutics

3. https://www.mahalo.health/insights/how-is-technology-revolutionizing-preventive-healthcare

4. https://www.clinicalleader.com/doc/trends-in-digital-therapeutics-for-0001

5. https://www.grandviewresearch.com/industry-analysis/digital-therapeutics-market#:~:text=Digital%20Therapeutics%20Market%20Size%20&%20Trends,to%20fuel%20the%20market%20growth.

6. https://www.fortunebusinessinsights.com/digital-therapeutics-market-103501

7. https://dtxalliance.org/wp-content/uploads/2021/01/DTA_FS_DTx-Product-Categories_010521.pdf

8. https://dtxalliance.org/understanding-dtx/#:~:text=Digital%20therapeutics%20are%20essential%20to,clinically%20safe%20and%20effective%20therapies

9. https://www.biospace.com/press-releases/life-sciences-revolution-advancements-shaping-the-next-decade

10. https://tracxn.com/d/sectors/chronic-disease-management/__tWXj6KXriaUeCJuFuE0x5L1zkiMVo2uiPEcw6heKeRg#about

11. https://ioplus.nl/en/posts/venture-capitalists-focus-on-digital-therapeutics-for-chronic-diseases-and-preventive-healthcare

12. https://www.lindushealth.com/blog/digital-therapeutics

13. https://www.mckinsey.com/industries/life-sciences/our-insights/the-health-benefits-and-business-potential-of-digital-therapeutics

14. https://www.mckinsey.com/industries/life-sciences/our-insights/the-promise-of-digital-therapeutics

15. https://medwave.io/2024/02/the-challenges-and-opportunities-of-digital-therapeutics-dtx-reimbursement/#:~:text=Providers%20also%20face%20integration%20challenges,integration%20of%20emerging%20digital%20modalities. 

Appendix

Source: IQVIA Institute, Sep 2024 Digital Health Trends 2024 

Source: Dealroom.co